Fig. 1From: The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005)Flow chart of patients through this SYSUCC-005 trialBack to article page